PrNMI

CAS No. 1541244-33-0

PrNMI( —— )

Catalog No. M12180 CAS No. 1541244-33-0

PrNMI is a peripherally restricted cannabinoid 1 receptor (CB1R) agonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 745 Get Quote
10MG 1017 Get Quote
25MG 1431 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PrNMI
  • Note
    Research use only, not for human use.
  • Brief Description
    PrNMI is a peripherally restricted cannabinoid 1 receptor (CB1R) agonist.
  • Description
    PrNMI is a peripherally restricted cannabinoid 1 receptor (CB1R) agonist, significantly alleviates spontaneous pain behaviors in the animals.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Cannabinoid Receptor
  • Recptor
    Cannabinoid Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1541244-33-0
  • Formula Weight
    409.573
  • Molecular Formula
    C29H31NO
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    4-{2-[-(1E)-1[(4-propylnaphthalen-1-yl)methylidene]-1H-inden-3-yl]ethyl}morpholine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhang H, et al. Pain. 2018 May 16. doi: 10.1097/j.pain.0000000000001278.
molnova catalog
related products
  • AM-1221

    A potent and selective agonist for the cannabinoid receptor CB1 with Ki of 0.28 nM, 180-fold selectivity over CB2.

  • AM-2201

    A synthetic cannabinoid that acts as a potent, nonselective full agonist for the cannabinoid receptor with EC50 of 38 and 58 nM for CB1 and CB2, respectively.

  • CB2R PAM

    CB2R PAM is an orally active cannabinoid type 2 receptor (CB2Rs) positive allosteric modulator that enhances CP 55940 and 2-Arachidonylglycerol-stimulated [35S]GTPγS binding to CB2 receptors without affecting receptor activity in the absence of agonists.